You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 04/24/2014

Company Name Symbol %Change
VERTEX ENERG VTNR
10.59%
MODINE MANUF MOD
8.77%
CLAYTON WILL CWEI
7.27%
INFINERA COR INFN
6.01%
E*TRADE FINA ETFC
5.44%
Pediatrics Partnering Terms and Agreements

Print Share

Dec 20, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/q6xzmw/pediatrics) has announced the addition of the "Pediatrics Partnering Terms and Agreements" company profile to their offering. The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter pediatrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pediatrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 500 links to online copies of actual pediatrics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of pediatrics dealmaking and business activities. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in pediatrics dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development. Chapter 3 provides a review of the leading pediatrics deals since 2007. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of pediatrics deals, as well as contract documents available in the public domain. Chapter 5 provides comprehensive access to all pediatrics deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Chapter 6 provides a comprehensive directory of all pediatrics partnering deals signed and announced since 2007. The chapter is organized by specific pediatrics therapy focus. In addition, a comprehensive appendix is provided with each report of all pediatrics partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in pediatrics partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pediatrics technologies and products. Company Profiles: - Abbott - Allergan - AstraZeneca - Baxter International - Biogen Idec - Bristol-Myers Squibb - Daiichi Sankyo - Eisai - Forest Laboratories - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Shionogi - Teva For more information visit http://www.researchandmarkets.com/research/q6xzmw/pediatrics

CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Pharmaceuticals (http://www.researchandmarkets.com/categories.asp?cat_id=88&campaign_id=q6xzmw)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2012 M2 COMMUNICATIONS

**********************************************************************

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
04-16-2012 for BAX @ $55.10.

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
03-13-2012 for BMY @ $33.26.

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
01-03-2012 for FRX @ $30.68.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.